Tivdak (tisotumab vedotin-tftv) / Genmab, Pfizer, Seagen, ZAI Lab 
Welcome,         Profile    Billing    Logout  

6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tivdak (tisotumab vedotin-tftv) / Genmab, Pfizer
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
ENGOT-cx20, NCT06459180: A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/)

Recruiting
3
686
Europe, US, RoW
Sacituzumab Tirumotecan, MK-2870, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan
Merck Sharp & Dohme LLC, European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Cervical Cancer
10/28
10/28
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Recruiting
2
692
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
04/25
11/26
2017-004758-40: Efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) monotherapy in combination in recurrent or Stage IVB cervical cancer

Ongoing
1/2
140
Europe, RoW
Tisotumab vedotin, HuMax®-TF-ADC, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Keytruda, Carboplatin, Avastin
Genmab A/S, GENMAB A/S, Genmab A/S
recurrent or stage IVB cervical cancer, cervical cancer, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-834, NCT03786081 / 2017-004758-40: Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Active, not recruiting
1/2
214
Europe, US, RoW
Tisotumab Vedotin, TIVDAK, Bevacizumab, Avastin, Pembrolizumab, KEYTRUDA®, Carboplatin, Paraplatin
Seagen Inc., Genmab, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgian Gynaecological Oncology Group, GOG Foundation, Merck Sharp & Dohme LLC
Cervical Cancer
12/24
12/24
NCT05866354: To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies

Completed
1
19
RoW
Tisotumab Vedotin
Zai Lab (Shanghai) Co., Ltd.
Solid Malignancies
11/23
11/23

Download Options